Herantis Pharma aktie (HRTIS) | Pressmeddelande - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Kom igång: Så börjar du spara i fonder 2025 – bästa tipsen för att komma igång (stor guide)

Pressmeddelanden från Herantis Pharma

 Bevaka pressreleaser
Kurs från TradingView
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

Herantis Pharma presenterar på BioStock Life Science Summit 20 november

Den sjunde upplagan av BioStock Life Science Summit går av stapeln 20-21 november, i Lund.

Cision • 04 Nov 11:00

Herantis Pharma will present at the BioStock Life Science Summit, November 20

The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21.

Cision • 04 Nov 11:00

Herantis julkaisee vuoden 2023 toisen vuosipuoliskon katsauksen ja vuoden 2023 tilinpäätöksen

Herantis julkaisee vuoden 2023 toisen vuosipuoliskon katsauksen ja vuoden 2023 tilinpäätöksen

MFN • 06 Mar 07:00

Herantis Pharma: HER-096 edistää solustressistä kärsivien hermosolujen toiminnallista palautumista ja uusiutumista – kaksi posteriesitystä AD/PD 2024 -konferenssissa

Herantis Pharma: HER-096 edistää solustressistä kärsivien hermosolujen toiminnallista palautumista ja uusiutumista – kaksi posteriesitystä A...

MFN • 04 Mar 08:30

Kutsu Herantis Pharman webinaariin: Yhtiön puolivuosikatsaus ja vuoden 2023 tilinpäätös 6.3.2024

Herantis Pharma Oyj | Lehdistötiedote | xx.02.2024 klo xx:xx:xx EET

MFN • 19 Feb 09:00

Herantis Pharma osallistuu 19th Annual Biomarkers Congress- ja Biotechgate Digital Partnering -tapahtumiin

Herantis Pharma osallistuu 19th Annual Biomarkers Congress- ja Biotechgate Digital Partnering -tapahtumiin

MFN • 12 Feb 08:00

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle

MFN • 26 Jan 11:50

Osakkeenomistajien nimitystoimikunnan ehdotukset Herantis Pharma Oyj:n varsinaiselle yhtiökokoukselle 2024

Osakkeenomistajien nimitystoimikunnan ehdotukset Herantis Pharma Oyj:n varsinaiselle yhtiökokoukselle 2024

MFN • 15 Jan 11:30

Herantis Pharma osallistuu vuosittaiseen J. P. Morgan Healthcare -viikon tapahtumiin San Franciscossa

Herantis Pharma osallistuu vuosittaiseen J. P. Morgan Healthcare -viikon tapahtumiin San Franciscossa

MFN • 18 Dec 2023 12:05

Herantis Pharma’s financial calendar and annual general meeting for 2024

Herantis Pharma’s financial calendar and annual general meeting for 2024

MFN • 13 Dec 2023 16:10

Herantis Pharma Oyj: 1.071.429 uutta osaketta rekisteröity kaupparekisteriin

Herantis Pharma Oyj: 1.071.429 uutta osaketta rekisteröity kaupparekisteriin

MFN • 13 Dec 2023 16:05

Herantis Pharma Oyj: 2.147.710 uutta osaketta rekisteröity kaupparekisteriin

Herantis Pharma Oyj: 2.147.710 uutta osaketta rekisteröity kaupparekisteriin

MFN • 08 Dec 2023 14:20

Herantis Pharma on inderesTV December 11th

Herantis Pharma on inderesTV December 11th

MFN • 08 Dec 2023 07:00

Inside information: Herantis Pharma Plc successfully completes a directed share issue raising EUR 4.51 million

Company release, inside information, 5 December 2023 at 8:45 p.

MFN • 05 Dec 2023 19:45

Herantis Pharma ilmoittaa HER-096:n prekliinisten tutkimustulosten julkaisusta Cell Chemical Biology -julkaisusarjassa

Herantis Pharma ilmoittaa HER-096:n prekliinisten tutkimustulosten julkaisusta Cell Chemical Biology -julkaisusarjassa

MFN • 01 Dec 2023 08:00

Herantis Pharma Plc's resolutions of the Extraordinary General Meeting

Herantis Pharma Plc's resolutions of the Extraordinary General Meeting

MFN • 17 Nov 2023 11:15

Herantis Pharma Oyj:n osakkeenomistajien nimitystoimikunnan kokoonpano

Herantis Pharma Oyj:n osakkeenomistajien nimitystoimikunnan kokoonpano

MFN • 15 Nov 2023 19:25

Meet Herantis Pharma at BIO-Europe 2023 in Munich, Germany

Meet Herantis Pharma at BIO-Europe 2023 in Munich, Germany

MFN • 01 Nov 2023 09:00

Kutsu Herantis Pharma Oyj:n ylimääräiseen yhtiökokoukseen

Kutsu Herantis Pharma Oyj:n ylimääräiseen yhtiökokoukseen

MFN • 27 Oct 2023 09:45

Inside information: Herantis Pharma announces positive topline data from the Phase 1a clinical trial of HER-096, a disease modifying therapeutic developed for Parkinson’s disease

Herantis Pharma Plc, Inside information, Company release, 25 October 2023 at 10:30 a.

MFN • 25 Oct 2023 09:30

Herantis Pharma osallistuu lokakuussa 2023 neljään tapahtumaan

Herantis Pharma osallistuu lokakuussa 2023 neljään tapahtumaan

MFN • 28 Sep 2023 08:00

Sisäpiiritieto: Herantis Pharman CDNF-kehitykseen myönnettyjen lainojen pääomasta jätetään perimättä noin 4,5 miljoonaa euroa Business Finlandin päätöksen mukaisesti

Sisäpiiritieto: Herantis Pharman CDNF-kehitykseen myönnettyjen lainojen pääomasta jätetään perimättä noin 4,5 miljoonaa euroa Business Finla...

MFN • 24 Sep 2023 16:00

Herantis Pharma osallistuu syyskuussa 2023 Biotech-tapahtumiin: Sachs 23rd Annual Biotech Forum ja ØU Life Science Investor Conference

Herantis Pharma osallistuu syyskuussa 2023 Biotech-tapahtumiin: Sachs 23rd Annual Biotech Forum ja ØU Life Science Investor Conference

MFN • 04 Sep 2023 16:10

Herantis Pharma julkaisee vuoden 2023 puolivuosikatsauksen

Herantis Pharma julkaisee vuoden 2023 puolivuosikatsauksen

MFN • 24 Aug 2023 07:00

Herantis Pharma Plc: First healthy volunteers dosed in the part 2 of the HER-096 Phase 1a clinical study

Herantis Pharma Plc: First healthy volunteers dosed in the part 2 of the HER-096 Phase 1a clinical study

MFN • 22 Aug 2023 09:30

Kutsu Herantis Pharman webinaariin: Yhtiön puolivuosikatsaus 24.8.2023

Kutsu Herantis Pharman webinaariin: Yhtiön puolivuosikatsaus 24.

MFN • 14 Aug 2023 12:00

Herantis Pharma osallistuu kahteen tieteelliseen konferenssiin elokuussa 2023

Herantis Pharma osallistuu kahteen tieteelliseen konferenssiin elokuussa 2023

MFN • 07 Aug 2023 09:00

Herantis Pharma Plc’s shares subscribed with option rights

Herantis Pharma Plc’s shares subscribed with option rights

Cision • 19 Jul 2023 07:00

Herantis Pharma Plc announcing start of recruitment of healthy volunteers for part 2 of the ongoing Phase 1a clinical study of HER-096

Herantis Pharma Plc announcing start of recruitment of healthy volunteers for part 2 of the ongoing Phase 1a clinical study of HER-096

Cision • 04 Jul 2023 11:05

Herantis Pharma Oyj: Managers' Transactions – Aki Prihti

Herantis Pharma Oyj: Managers' Transactions – Aki Prihti

Cision • 20 Jun 2023 09:30

Herantis Pharma Oyj: Managers' Transactions – Frans Wuite

Herantis Pharma Oyj: Managers' Transactions – Frans Wuite

Cision • 20 Jun 2023 09:30

Herantis Pharma Oyj: Managers' Transactions – Timo Veromaa

Herantis Pharma Oyj: Managers' Transactions – Timo Veromaa

Cision • 20 Jun 2023 09:30

Herantis Pharma Oyj: Managers' Transactions – Henri Huttunen

Herantis Pharma Oyj: Managers' Transactions – Henri Huttunen

Cision • 20 Jun 2023 09:30

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle

Cision • 09 Jun 2023 13:17

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto

Cision • 09 Jun 2023 13:15

Herantis Pharma Oyj: Managers' Transactions – Henri Huttunen

Herantis Pharma Oyj: Managers' Transactions – Henri Huttunen

Cision • 09 Jun 2023 13:15

Herantis Pharma Plc's board decides on new option rights program for managing director, management team and other key personnel

Herantis Pharma Plc's board decides on new option rights program for managing director, management team and other key personnel

Cision • 02 Jun 2023 14:00

Herantis Pharma to participate in Bio€quity Europe 2023 in Dublin May 2023

Herantis Pharma to participate in Bio€quity Europe 2023 in Dublin May 2023

Cision • 02 May 2023 10:45

Decisions of Herantis Pharma Plc’s Annual General Meeting of shareholders

Decisions of Herantis Pharma Plc’s Annual General Meeting of shareholders

Cision • 20 Apr 2023 12:35

Herantis Pharma announces first healthy volunteer dosed in the Phase 1a clinical study for the Parkinson’s disease drug candidate, HER-096

Herantis Pharma announces first healthy volunteer dosed in the Phase 1a clinical study for the Parkinson’s disease drug candidate, HER-096

Cision • 19 Apr 2023 10:00

Herantis Pharma to participate in Nordic Health Summit Japan 2023

Herantis Pharma to participate in Nordic Health Summit Japan 2023

Cision • 06 Apr 2023 08:00

Notice to Convene Herantis Pharma Plc's Annual General Meeting of Shareholders

Notice to Convene Herantis Pharma Plc's Annual General Meeting of Shareholders

Cision • 28 Mar 2023 12:46

Herantis Pharma published the Annual report for 2022

Herantis Pharma published the Annual report for 2022

Cision • 28 Mar 2023 07:00

Herantis Pharma to participate in Bio-Europe Spring and AD/PD 2023

Herantis Pharma to participate in Bio-Europe Spring and AD/PD 2023

Cision • 09 Mar 2023 08:00

Herantis publishes 2H & FY 2022 Report

Herantis publishes 2H & FY 2022 Report

Cision • 02 Mar 2023 07:00

Herantis Pharma: Invitation to 2H & FY 2022 report webinar on March 2, 2023

Herantis Pharma: Invitation to 2H & FY 2022 report webinar on March 2, 2023

Cision • 21 Feb 2023 12:00

Herantis Pharma announces approval of Clinical Trial Application (CTA) for a Phase 1 study for HER-096

Herantis Pharma announces approval of Clinical Trial Application (CTA) for a Phase 1 study for HER-096

Cision • 20 Feb 2023 12:00

Proposals of the Shareholders' Nomination Committee to Herantis Pharma Plc's Annual General Meeting 2023

Proposals of the Shareholders' Nomination Committee to Herantis Pharma Plc's Annual General Meeting 2023

Cision • 20 Jan 2023 09:00

Herantis Pharma: Key takeaways from todays R&D update webinar

Herantis Pharma: Key takeaways from todays R&D update webinar

Cision • 19 Jan 2023 12:00

Herantis Pharma to host a R&D update webinar on January 19, 2023

Herantis Pharma to host a R&D update webinar on January 19, 2023

Cision • 12 Jan 2023 08:00

Herantis Pharma to participate in Biotech Showcase and Sachs virtual conferences

Herantis Pharma to participate in Biotech Showcase and Sachs virtual conferences

Cision • 04 Jan 2023 08:00

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle

Cision • 22 Dec 2022 10:00

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto

Cision • 22 Dec 2022 10:00

Herantis Pharma Oyj: Managers' Transactions – Henri Huttunen

Herantis Pharma Oyj: Managers' Transactions – Henri Huttunen

Cision • 22 Dec 2022 10:00

Herantis Pharma to host a R&D update webinar January 19, 2023

Herantis Pharma to host a R&D update webinar January 19, 2023

Cision • 20 Dec 2022 12:00

Herantis Pharma selected for European Innovation Council (EIC) grant of €2.5 million

Herantis Pharma selected for European Innovation Council (EIC) grant of €2.

Cision • 19 Dec 2022 16:30

Herantis Pharma announces submission of a Clinical Trial Application (CTA) for a Phase 1 study for HER-096

Herantis Pharma announces submission of a Clinical Trial Application (CTA) for a Phase 1 study for HER-096

Cision • 19 Dec 2022 13:15

Herantis Pharma’s financial calendar and annual general meeting for 2023

Herantis Pharma’s financial calendar and annual general meeting for 2023

Cision • 15 Dec 2022 08:00

Herantis Pharma to participate in Inderes Life Science evening

Herantis Pharma to participate in Inderes Life Science evening

Cision • 07 Dec 2022 08:00

Herantis Pharma: Approved delisting application regarding the secondary listing on the Nasdaq First North Growth Market Sweden

Herantis Pharma: Approved delisting application regarding the secondary listing on the Nasdaq First North Growth Market Sweden

Cision • 05 Dec 2022 08:00

Herantis Pharma applies for delisting regarding the secondary listing of its shares from Nasdaq First North Growth Market Sweden

Herantis Pharma applies for delisting regarding the secondary listing of its shares from Nasdaq First North Growth Market Sweden

Cision • 01 Dec 2022 10:30

Herantis Pharma to participate in upcoming November investor conferences

Herantis Pharma to participate in upcoming November investor conferences

Cision • 07 Nov 2022 08:00

Composition of Herantis Pharma Plc’s Shareholders’ Nomination Committee

Composition of Herantis Pharma Plc’s Shareholders’ Nomination Committee

Cision • 26 Oct 2022 16:30

Herantis Pharma will attend Bio-Europe 2022 and Redeye Neurology Day

Herantis Pharma will attend Bio-Europe 2022 and Redeye Neurology Day

Cision • 05 Oct 2022 14:30

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto

Cision • 21 Sep 2022 16:00

Herantis Pharma Plc's board decides on new option rights program for managing director, management team and other key personnel

Herantis Pharma Plc's board decides on new option rights program for managing director, management team and other key personnel

Cision • 15 Sep 2022 14:30

Herantis Pharma to Participate in the Nordic Life Science Days, Sweden

Herantis Pharma to Participate in the Nordic Life Science Days, Sweden

Cision • 07 Sep 2022 08:00

Herantis publishes 1H Report for 2022

Herantis publishes 1H Report for 2022

Cision • 25 Aug 2022 07:00

Herantis Pharma: Invitation to 1H 2022 Report on August 25, 2022

Herantis Pharma: Invitation to 1H 2022 Report on August 25, 2022

Cision • 04 Aug 2022 08:00

Antti Vuolanto appointed as CEO of Herantis as of 22 July 2022

Antti Vuolanto appointed as CEO of Herantis as of 22 July 2022

Cision • 08 Jul 2022 12:00

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle

Cision • 02 Jun 2022 15:00

Herantis Pharma Oyj: Managers' Transactions – Frans Wuite

Herantis Pharma Oyj: Managers' Transactions – Frans Wuite

Cision • 02 Jun 2022 15:00

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto

Cision • 02 Jun 2022 15:00

New shares in Herantis Pharma Plc registered with the trade register

New shares in Herantis Pharma Plc registered with the trade register

Cision • 02 Jun 2022 10:10

Final results of Herantis Pharma Plc's fully subscribed rights issue

Final results of Herantis Pharma Plc's fully subscribed rights issue

Cision • 01 Jun 2022 19:00

Preliminary results of Herantis Pharma Plc's fully subscribed rights issue

Preliminary results of Herantis Pharma Plc's fully subscribed rights issue

Cision • 30 May 2022 18:45

Herantis Pharma to Participate in Redeye Growth Day in June

Herantis Pharma to Participate in Redeye Growth Day in June

Cision • 27 May 2022 12:00

BioStock: Herantis tar sista steget mot klinik med emission

Parkinsons är i dag världens näst vanligaste neurodegenerativa sjukdom.

Cision • 19 May 2022 09:04

BioStock Studio: Herantis Pharma om emissionen

Finska Herantis Pharma utvecklar sin kandidat HER-096 mot den svåra neurodegenerativa sjukdomen Parkinsons och är just nu aktuella med en em...

Cision • 17 May 2022 08:38

Herantis Pharma Oyj: Managers' Transactions – Timo Veromaa

Herantis Pharma Oyj: Managers' Transactions – Timo Veromaa

Cision • 13 May 2022 08:00

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle

Cision • 13 May 2022 08:00

Herantis Pharma Oyj: Managers' Transactions – Frans Wuite

Herantis Pharma Oyj: Managers' Transactions – Frans Wuite

Cision • 13 May 2022 08:00

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto

Cision • 13 May 2022 08:00

Herantis Pharma: Invitation to a virtual company presentation on May 19, 2022

Herantis Pharma: Invitation to a virtual company presentation on May 19, 2022

Cision • 12 May 2022 10:00

BioStock: Herantis tf vd om emission och vägen mot klinik

Parkinsons är en svår neurodegenerativ sjukdom där det i dagsläget endast finns symptomlindrande behandling att tillgå för den som drabbats.

Cision • 12 May 2022 08:33

BioStock Investor Pitch: Herantis Pharma

Välkommen att ta del av Herantis Pharmas bolagspresentation idag 10 maj kl 10:00.

Cision • 10 May 2022 08:41

Herantis Pharma Plc's publishes a prospectus relating to its rights issue

Herantis Pharma Plc's publishes a prospectus relating to its rights issue

Cision • 03 May 2022 18:50

Herantis Pharma Plc's Board of Directors resolved on a rights issue and publishes the terms and conditions of the rights issue

Herantis Pharma Plc's Board of Directors resolved on a rights issue and publishes the terms and conditions of the rights issue

Cision • 03 May 2022 10:23

Herantis Pharma to Participate in Investor and Partnering Conferences

Herantis Pharma to Participate in Investor and Partnering Conferences

Cision • 02 May 2022 10:15

Herantis Pharma Announces Successful HER-096 Initial Results with Blood-Brain Barrier Penetration in Dogs

Herantis Pharma Announces Successful HER-096 Initial Results with Blood-Brain Barrier Penetration in Dogs

Cision • 28 Apr 2022 08:00

Decisions of Herantis Pharma Plc’s Annual General Meeting of shareholders

Decisions of Herantis Pharma Plc’s Annual General Meeting of shareholders

Cision • 21 Apr 2022 12:20

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle

Cision • 14 Apr 2022 15:00

Herantis Pharma Oyj: Managers' Transactions – Sigrid Booms

Herantis Pharma Oyj: Managers' Transactions – Sigrid Booms

Cision • 14 Apr 2022 15:00

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto

Cision • 14 Apr 2022 15:00

Herantis Pharma Oyj: Managers' Transactions – Henri Huttunen

Herantis Pharma Oyj: Managers' Transactions – Henri Huttunen

Cision • 14 Apr 2022 15:00

Herantis Pharma Plc – allocation of option rights

Herantis Pharma Plc – allocation of option rights

Cision • 13 Apr 2022 16:32

Herantis Pharma Plc: Managers' transactions – Inveni Capital Oy

Herantis Pharma Plc: Managers' transactions – Inveni Capital Oy

Cision • 05 Apr 2022 13:42

Herantis Pharma Plc: Managers' transactions – Inveni Fund I Oy

Herantis Pharma Plc: Managers' transactions – Inveni Fund I Oy

Cision • 05 Apr 2022 13:36

Herantis Pharma Plc: Managers' transactions – Inveni Life Sciences Fund I Ky

Herantis Pharma Plc: Managers' transactions – Inveni Life Sciences Fund I Ky

Cision • 05 Apr 2022 13:30

Correction to the notice of Annual General Meeting of Shareholders of Herantis Pharma Plc

Correction to the notice of Annual General Meeting of Shareholders of Herantis Pharma Plc

Cision • 05 Apr 2022 11:50